Medical treatment of portal hypertension

Best Practice and Research: Clinical Gastroenterology

Volumn 14, Issue 6, 2000, Pages 895-909

  García Pagán, Juan Carlos ^a   Bosch, Jaime ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Liver cirrhosis; Portal hypertension; Propranolol; Vasoactive agents

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALCOHOL; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; ETHANOLAMINE; GLYCERYL TRINITRATE; ISOSORBIDE 5 NITRATE; MORRHUATE SODIUM; NADOLOL; OCTREOTIDE; ORGANIC NITRATE; POLIDOCANOL; PROPRANOLOL; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SPIRONOLACTONE; TERLIPRESSIN; VASOCONSTRICTOR AGENT; VASODILATOR AGENT; VASOPRESSIN;

ADULT; APATHY; ARTICLE; BLEEDING; BRADYCARDIA; BRONCHOSPASM; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DYSPHAGIA; DYSPNEA; ENDOSCOPIC THERAPY; ENDOSCOPY; ESOPHAGUS PERFORATION; ESOPHAGUS STENOSIS; ESOPHAGUS VARICES BLEEDING; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; IMPOTENCE; INSOMNIA; MAJOR CLINICAL STUDY; ORTHOSTATIC HYPOTENSION; PLEURA EFFUSION; PORTAL HYPERTENSION; PORTOSYSTEMIC ANASTOMOSIS; PROPHYLAXIS; SCLEROTHERAPY; SEPSIS; SIDE EFFECT; STOMACH VARICES; THROMBOSIS; VEIN LIGATION;

EID: 0034515215     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2000.0137     Document Type: Article

References (48)

1. Complications of cirrhosis. Portal hypertension
2. The treatment of portal hypertension: A meta-analytic review
3. Hemodynamic events in a prospective randomized trial of propranolol vs. placebo in the prevention of the first variceal hemorrhage
4. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study
5. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis
6. Pharmacological prevention of variceal bleeding. New developments. Portal hypertension
7. Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function
8. Beta-adrenergic blockers and nitrovasodilators for the treatment of portal hypertension: The good, the bad and the ugly
9. Portal pumping: A new perspective for treatment of variceal hemorrhage and liver failure in end-stage cirrhosis?
10. Influence of pharmacological agents on portal hemodynamics: Basis for its use in the treatment of portal hypertension
11. Effects of low sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis
12. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study
13. Endoscopic treatments for portal hypertension
14. Beta-adrenergic antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices: An analysis of data and prognostic factors in 589 patients from four randomised clinical trials
15. Prevention of first bleeding in cirrhosis. A metaanalysis of randomized trials of nonsurgical treatment
16. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function
17. Long-term haemodynamic effects of isosorbide-5-mononitrate in patients with cirrhosis and portal hypertension
18. Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic hemodynamics in patients with cirrhosis
19. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis
20. Long-term administration of isosorbide-5-mononitrate does not impair renal function in cirrhotic patients
21. Effects of isosorbide-5-mononitrate compared with propranolol on first bleeding and long-term survival in cirrhosis
22. Nadolol and isosorbide-5-mononitrate for preventing bleeding in cirrhotics with ascites
23. Isosorbide-5-mononitrate vs placebo in the prevention of the first variceal bleeding in patients with contraindications or intolerance to beta-blockers
24. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis
25. Isosorbide mononitrate (IMN) with nadolol compared to nadolol alone for prevention of first bleeding in cirrhosis. A double-blind placebo-controlled randomised trial
26. Propranolol + placebo vs propranolol + isosorbide-5-mononitrate in the prevention of the first variceal bleeding. A multicenter double blind randomized controlled trial
27. Pharmacological treatment of portal hypertension: An evidence-based approach
28. Continuous prazosin administration in cirrhotic patients: Effects on portal hemodynamics and on liver and renal function
29. Transjugular intrahepatic portosystemic shunt
30. A randomized controlled trial of endoscopic variceal band ligation for primary prophylaxis of variceal bleeding
31. Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high risk varices
32. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding
33. Clinical events after transjugular intrahepatic portosystemic shunt: Correlation with hemodynamic findings
34. Terlipressin in bleeding esophageal varices. A placebo controlled double-blind study
35. Placebo-controlled trial of terlipressin (glypressin) in the management of acute variceal bleeding
36. Terlipressin (triglycyl-lysine vasopressin) controls acute bleeding oesophageal varices. A double-blind, randomized, placebo-controlled trial
37. Randomized controlled trial comparing terlipressin vs endoscopic sclerotherapy in the treatment of acute variceal bleeding and prevention of early rebleeding
38. Early administration of terlipressin plus glyceril trinitrat to control active upper gastrointestinal bleeding in cirrhotic patients
39. Terlipressin versus somatostatin in the treatment of bleeding esophageal varices. Final report of a placebo-controlled, double blind study
40. Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage
41. A prospective randomised controlled trial comparing the efficacy of somatostatin with injection sclerotherapy in the control of oesophageal varices
42. A prospective randomized trial comparing somatostatin and sclerotherapy in the treatment of acute variceal bleeding
43. Sclerotherapy with or without octreotide for acute variceal bleeding
44. Prospective randomised study of effect of octreotide on rebleeding from oesophageal varices after endoscopic ligation
45. Double blind RCT of 5 day octreotide versus placebo, associated with sclerotherapy for trial failures
46. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis and portal hypertension. A double-blind hemodynamic investigation
47. Randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding
48. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: The European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial